Amicus Therapeutics, Inc. FOLD
14.49 USD 0.00 (+0.00%)
At closeApr 27, 2026, 4:00 PM EDT
14.49 0.00 0.00%
After hours · Apr 27, 4:00 PM ET
14.49 Day range 14.49
52-week range unavailable
- YTD
- +1.76%
- 1 year
- +97.14%
Analyst view
Price target (mean) —
Ratings (0m) 12 9 buy · 3 hold · 0 sell
- Strong buy8
- Buy1
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.0819 | -0.0819 – -0.0819 | 0.03 | -372.8% | 159.64M | +27.5% | 1 |
| Current quarter | 0.1224 | 0.1118 – 0.13 | 0.10 | +22.4% | 165.16M | +16.7% | 5 |
| Current quarter | 0.0172 | -0.03 – 0.07 | 0.06 | -71.4% | 146.68M | +15.8% | 5 |
| Current quarter | 0.0809 | 0.05 – 0.1235 | -0.02 | +504.3% | 136.35M | +23.5% | 4 |
| Current quarter | 0.00 | -0.05 – 0.04 | -0.07 | +100.0% | 135.33M | +30.8% | 9 |
| Current quarter | -0.05 | -0.10 – 0.02 | -0.15 | +66.7% | 121.24M | +28.3% | 11 |
| Current quarter | -0.07 | -0.10 – -0.03 | -0.18 | +61.1% | 111.19M | +33.8% | 9 |
| Current quarter | -0.08 | -0.09 – -0.04 | -0.12 | +33.3% | 101.36M | +20.4% | 9 |
| Current quarter | -0.12 | -0.18 – -0.09 | -0.21 | +42.9% | 89.87M | +11.3% | 9 |
| Current quarter | -0.15 | -0.20 – -0.07 | -0.30 | +50.0% | 83.08M | +5.5% | 9 |
| Current quarter | -0.19 | -0.23 – -0.08 | -0.19 | 0.0% | 84.22M | +5.9% | 11 |
| Current quarter | -0.22 | -0.29 – -0.15 | -0.19 | -15.8% | 85.89M | +17.0% | 10 |
| Current quarter | -0.25 | -0.31 – -0.14 | -0.25 | 0.0% | 77.13M | +16.2% | 10 |
| Current quarter | -0.18 | -0.21 – -0.15 | -0.25 | +28.0% | 80.11M | 0.0% | 10 |
| Current quarter | -0.22 | -0.26 – -0.20 | -0.20 | -10.0% | 77.41M | +24.1% | 11 |
| Current quarter | -0.24 | -0.27 – -0.18 | -0.35 | +31.4% | 71.65M | +18.4% | 9 |
| Current quarter | -0.22 | -0.27 – -0.14 | -0.24 | +8.3% | 65.10M | +33.5% | 13 |
| Current quarter | -0.26 | -0.33 – -0.15 | -0.36 | +27.8% | 62.38M | 0.0% | 13 |
| Current quarter | -0.28 | -0.38 – -0.22 | -0.56 | +50.0% | 57.49M | +51.8% | 12 |
| Current quarter | -0.32 | -0.37 – -0.28 | -0.84 | +61.9% | 47.66M | 0.0% | 12 |
| Current quarter | -0.33 | -0.38 – -0.27 | -0.33 | 0.0% | 41.13M | +93.0% | 11 |
| Current quarter | -0.31 | -0.40 – -0.23 | -0.28 | -10.7% | 37.86M | +126.8% | 10 |
| Current quarter | -0.28 | -0.31 – -0.25 | -0.69 | +59.4% | 23.57M | +116.8% | 7 |
| Current quarter | -0.33 | -0.35 – -0.29 | -0.34 | +2.9% | 19.16M | +167.7% | 6 |
| Current quarter | -0.36 | -0.39 – -0.34 | -0.39 | +7.7% | 16.89M | +305.1% | 6 |
| Current quarter | -0.31 | -0.38 – -0.26 | -0.33 | +6.1% | 9.52M | +347.6% | 7 |
| Current quarter | -0.36 | -0.41 – -0.31 | -0.40 | +10.0% | 6.69M | 0.0% | 6 |
| Next quarter | 0.0157 | 0.0157 – 0.0157 | 0.01 | +57.1% | 180.88M | +16.9% | 1 |
| Current year | 0.0726 | 0.0726 – 0.0726 | 0.31 | -76.6% | 752.43M | +18.6% | 1 |
| Current year | 0.393 | 0.35 – 0.44 | 0.24 | +63.7% | 634.00M | +20.0% | 4 |
| Current year | 0.2357 | 0.13 – 0.2983 | -0.13 | +281.3% | 527.02M | +32.0% | 5 |
| Current year | -0.45 | -0.50 – -0.41 | -0.82 | +45.1% | 398.67M | +21.1% | 9 |
| Current year | -0.77 | -0.86 – -0.64 | -0.92 | +16.3% | 327.42M | +7.2% | 11 |
| Current year | -0.78 | -0.84 – -0.72 | -1.07 | +27.1% | 307.10M | +17.7% | 10 |
| Current year | -1.02 | -1.13 – -0.92 | -1.48 | +31.1% | 259.93M | +42.6% | 7 |
| Current year | -1.38 | -1.45 – -1.31 | -1.88 | +26.6% | 179.29M | +96.5% | 11 |
| Current year | -1.74 | -1.77 – -1.72 | -1.85 | +5.9% | 89.67M | +142.8% | 9 |
| Current year | -1.60 | -1.77 – -1.20 | -1.49 | -7.4% | 36.00M | +626.1% | 6 |
| Next year | 0.8189 | 0.4656 – 0.97 | 0.0726 | +1028.8% | 888.54M | +18.1% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 22, 2026 | Jefferies | Downgrade | Buy | Hold |
| Dec 29, 2025 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Dec 22, 2025 | Citigroup | Downgrade | Buy | Neutral |
| Dec 19, 2025 | Needham | Downgrade | Buy | Hold |
| Dec 19, 2025 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| Dec 17, 2025 | Citigroup | Initiated | — | Buy |
| Nov 6, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Nov 5, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Sep 18, 2025 | Needham | Upgrade | Hold | Buy |
| Jul 17, 2025 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| May 2, 2025 | UBS | Maintained | Buy | Buy |
| May 2, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Feb 20, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Feb 20, 2025 | Needham | Reiterated | Hold | Hold |
| Jan 15, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Jan 13, 2025 | Needham | Reiterated | Hold | Hold |
| Dec 13, 2024 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Nov 12, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Nov 7, 2024 | Guggenheim | Maintained | Buy | Buy |
| Nov 7, 2024 | UBS | Maintained | Buy | Buy |
| Nov 7, 2024 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Nov 7, 2024 | Needham | Reiterated | — | Hold |
| Oct 17, 2024 | B of A Securities | Maintained | Buy | Buy |
| Oct 11, 2024 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 20, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 6, 2024 | Jefferies | Initiated | — | Buy |
| Aug 16, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 9, 2024 | Needham | Reiterated | — | Hold |
| May 30, 2024 | Wells Fargo | Initiated | — | Overweight |
| May 14, 2024 | Guggenheim | Upgrade | Neutral | Buy |